Long-term SARS Coronavirus Excretion from Patient Cohort, China by Liu, Wei et al.
Long-term SARS
Coronavirus
Excretion from
Patient Cohort,
China 
Wei Liu,* Fang Tang,* Arnaud Fontanet,† 
Lin Zhan,* Qiu-Min Zhao,* Pan-He Zhang,* 
Xiao-Ming Wu,* Shu-Qing Zuo,* Laurence Baril,†
Astrid Vabret,‡ Zhong-Tao Xin,§ Yi-Ming Shao,¶
Hong Yang,* and Wu-Chun Cao*
This study investigated the long-term excretion of
severe acute respiratory syndrome–associated coronavirus
in sputum and stool specimens from 56 infected patients.
The median (range) duration of virus excretion in sputa and
stools was 21 (14–52) and 27 (16–126) days, respectively.
Coexisting illness or conditions were associated with longer
viral excretion in stools. 
S
evere acute respiratory syndrome (SARS) is a newly
emerged disease that spread globally in early 2003;
more than 2,523 cases and 181 deaths occurred in Beijing,
China (1–3). In the initial outbreak period, the diagnosis of
infection was mostly dependent on clinical manifestations
and epidemiologic findings, until the associated coron-
avirus (SARS-CoV) was identified as the causal agent
(4–6), and its immediate full genome was sequenced (7,8).
Molecular assays using reverse transcriptase–poly-
merase chain reaction (RT-PCR) were developed as an
important diagnostic tool on a variety of clinical samples
(4–6,9). Several studies have explored the optimal source
and timing of sample collection for SARS diagnosis on the
basis of RT-PCR results (5,10–12). While viral genetic
material could be detected by RT-PCR in stools for up to
50 days, no virus could be cultured after 3 weeks of illness
from corresponding specimens (12). Although long-term
viral excretion has important public health implications
through its potential spread of the virus to the environ-
ment, no study has yet explored factors associated with
prolonged viral excretion and risk for transmission to
household contacts. Our study was designed to investigate
prospectively the viral shedding from a cohort of Beijing
SARS patients for up to 6 months. Clinical and epidemio-
logic data were used to identify the potential risk factors
for prolonged virus shedding. Household contacts of
SARS patients were clinically monitored for secondary
transmission. 
The Study
Patients were recruited for the study at one of the des-
ignated hospitals for SARS patients in Beijing. The diag-
nosis of probable SARS was made in accordance with the
definition promulgated by the World Health Organization.
Briefly, the case definition included the following: fever of
>38°C, cough or shortness of breath, new pulmonary infil-
trates on chest radiography, and a history of exposure to a
patient with SARS or absence of response to empirical
antimicrobial therapy for typical and atypical pneumonia.
Stool and sputum specimens from probable SARS patients
were collected weekly while they were in the hospital and
monthly after they were discharged, up to 6 months after
onset of disease. Specimens were transported in viral
transport medium and stored at –70°C until testing.
After informed consent was obtained, epidemiologic
and clinical data were collected from all study participants
by using a standard data collection form, through interview
and medical record review. The obtained information
included the following items: age, sex, occupation, med-
ical history, time and nature of exposure, symptoms and
physical findings, laboratory tests at admission to the hos-
pital, and outcomes on discharge. Aquestionnaire was also
used to identify any suspected or probable SARS case
among household contacts of SARS patients after they
were discharged. The questionnaire was administered 1
month after discharge from the hospital, and at the end of
the followup period.
Specimens were analyzed after the RT-PCR protocol
was optimized in the laboratory. Early samples from all
patients were tested, and only patients with at least one
sample that tested positive for SARS-CoV RNAduring the
first 16 days were kept in the study. All subsequent sam-
ples from the same patients were then tested until three
consecutive samples were negative; the first negative sam-
ple defined the time of negativation. RNA from clinical
samples was extracted by using the QIAamp virus RNA
mini kit (Qiagen, Hilden, Germany), as instructed by the
manufacturer. Total RNA was then reverse transcribed
with random hexamers, and cDNAwas amplified with two
primer pairs. The first pair, COR-1/COR-2, is one of the
primer pairs recommended by the World Health
Organization (http://www.who.int/csr/SARS/primers/en/).
The second pair, R1/R2, was designed to amplify a 220-bp
fragment of the replicase gene (R1: 5′ AGG TTA GCT
AAC GAG TGT GCG 3′, R2: 5′AGC CTG TGT TGT
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People’s Republic of ChinaAGA TTG CGG 3′). These two primer pairs, COR-
1/COR-2 and R1/R2, had been selected among others
(including Cor-p-F2/Cor-p-R1, Cor-p-F3/Cor-p-R1,
SAR1s/SAR1as) for their higher sensitivity (87% and
95%, respectively), using serologic testing as the standard.
Congruence between the results of the two tests was 86%
(F. Tang, pers. comm.). Only specimens with positive
results for both primer pairs were considered positive, so
that false-positive results were eliminated. During this pro-
cedure, positive and negative controls were systematically
included and treated in the same way as the virus sample.
Viral isolation was performed on RT-PCR–positive
stool samples from convalescent patients only. The sample
was pretreated by centrifugation, and the supernatant was
injected after filtration into the VeroE6 cell culture at
37°C. All procedures were handled under biosafety level 3
conditions. We looked for the characteristic cytopathic
effect for 5 to 11 days after injection. Examination with
electron microscope and RT-PCR assays were used for
identification of SARS-CoV.
All data were processed by SPSS (SPSS Inc. Chicago,
IL) and Stata (Stata Corporation, College Station, TX)
software. Categorical and continuous variables were com-
pared across study groups by means of χ2, Fisher exact
test, and Mann-Whitney U tests, where appropriate.
Survival analysis was performed by using time to RT-PCR
negativation as the outcome variable (for stool and sputum
specimens separately). Survival curves were built by using
the Kaplan-Meier method. Correlation coefficient between
time to RT-PCR negativation in stools and sputum was cal-
culated by using the Spearman rank correlation coefficient.
From mid-March to early May 2003, a total of 83 prob-
able SARS patients were admitted to a Beijing hospital
dedicated to SARS patients. Of these, 56 (67.4%) had at
least one RT-PCR–positive sample in the first 16 days of
hospitalization and were therefore enrolled in the study.
The study group consisted of 31 male and 25 female par-
ticipants, with a median age of 31 and 34 years, respective-
ly. Of the 56 patients, 21 (37.5%) were healthcare workers.
The median (range) duration between onset of symptoms
and hospitalization was 2 (0–6) days, and the median
(range) duration of hospital stay was 32 (21–58) days. Six
patients had coexisting medical conditions or illnesses at
enrollment or during followup: diabetes (2 patients), heart
disease (2 patients), pulmonary tuberculosis (2 patients,
including 1 with diabetes), and high blood pressure
(1 patient). No patient died.
A total of 514 stool and 493 sputum specimens were
collected from the 56 patients during the study period. The
median (range) duration between onset of symptoms and
first positive RT-PCR test result was 6 (3–10) days for
stool and 6 (3–16) days for sputum. RT-PCR sputum and
stool specimens did not show negative results until day 14
and day 16 after disease onset, respectively (Figure). The
median (range) duration of viral excretion was 21 (14–52)
days for sputum samples, and 27 (16–126) days for stool
specimens. Negative RT-PCR results occurred at the same
time in sputum and stool samples for 45 patients, and at a
later time in stool samples than in sputum in 11 patients
(the Spearman rank correlation coefficient between time to
RT-PCR negativation in sputum and stool was 0.65, p <
0.0001). Four patients had viral excretion in stools after
100 days; three of these patients had coexisting conditions,
such as pulmonary tuberculosis (2 patients), diabetes (1
patient, who also had tuberculosis), and high blood pres-
sure (1 patient). The proportion of patients with coexisting
conditions was significantly higher for patients with viral
excretion >100 days compared to others (3/4 vs. 3/52, p =
0.003, Fisher exact test). All attempts (n = 12) to isolate
virus from RT-PCR–positive stool specimens collected >6
weeks after disease onset failed. All 56 patients had at least
one close contact. Clinical symptoms suggestive of SARS
did not develop in any of the 70 close contacts of conva-
lescent SARS patients we surveyed.
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Figure. Time lapse before sputum and stool specimens of patients
with severe acute respiratory syndrome (SARS) (N = 56) were
negative by reverse transcription-polymerase chain reaction, at
one designated SARS hospital, Beijing, 2003.Conclusions
This study is the first to document duration of SARS-
CoV excretion in sputum and stool in a cohort of SARS
patients. The median duration of viral excretion was 3
weeks in sputa and 4 weeks in stool samples. This estimate
might be high, since some patients with no or short viral
excretion might have been missed because of the study
design. In most patients (45 of 56), the duration of viral
excretion in both specimens was identical, while it was
longer in stool samples compared to sputa for 11 patients.
The long duration of excretion (>100 days after onset of
symptoms) observed in stools of four patients suggests that
independent replication of virus may take place in the
intestinal tract. Three of these four patients had coexisting
conditions, a known risk factor for prolonged SARS illness
(13,14). Prolonged viral excretion may have important
public health implications if responsible for spread of the
virus to other persons or to the environment. Two findings
of this study are reassuring in this regard: one is the failure
of all attempts to isolate the virus from positive RT-PCR
specimens collected in convalescent patients, which sug-
gests that excreted virus was no longer infectious; the other
is the absence of SARS in close contacts of convalescent
patients during the study period.
Our study has demonstrated long-term duration of
SARS-CoV excretion in stools. Careful hand and toilet
disinfection is required to avoid transmission of the virus
to close contacts of patients.
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